On Thursday, Shares of Molson Coors Brewing Company (NYSE:TAP), gained 0.13% to $ 74.86.
Molson Coors Brewing Company, declared that consumer product executive Mary Lynn Ferguson-McHugh will join its board of directors, effective right away.
Ferguson-McHugh is the Group President of Global Family Care for Procter & Gamble Company (PG), one of the world’s largest makers of consumer packaged goods. P&G has one of the strongest portfolios of trusted, quality, leadership brands, counting Always, Bounty, Charmin, Crest, Gillette, Olay, Oral-B, Pampers, Pantene and Tide.
Molson Coors Brewing Company manufactures and sells beer and other beverage products. The company sells its products under the Coors Light, Molson Canadian, Carling, Carling Black Label, Coors Altitude, Coors Banquet, Creemore Springs, the Granville Island, Keystone Light, Mad Jack, Molson Canadian 67, Molson Canadian Cider, Molson Dry, Molson Export, Pilsner, and the Rickard’s family brands in Canada; and brews or distributes under the Amstel Light, Heineken, Murphy’s, Newcastle Brown Ale, Strongbow cider, Desperados, Dos Equis, Moretti, Sol, Tecate, Miller Chill, and Miller Genuine Draft brands.
Shares of Medivation, Inc. (NASDAQ:MDVN), declined -3.84% to $116.06, during its last trading session.
In October 2009, Medivation (MDVN) and Astellas (TSE:4503) reached a global agreement to jointly develop and commercialize enzalutamide. The companies are collaborating on a comprehensive development program that comprises studies to develop enzalutamide across the full spectrum of advanced prostate cancer in addition to advanced breast cancer.
Astellas Pharma Inc. (Tokyo:4503) declared that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study met its primary endpoint and the abstract was also selected to be featured in the forthcoming ‘Best of ASCO’ meetings.
The Phase 2 open label single arm, multicenter trial enrolled 118 women with advanced TNBC in two stages. The primary endpoint of the trial was clinical benefit rate at 16 weeks (CBR16), defined as the proportion of women with a complete response (CR), partial response (PR) or stable disease for at least 16 weeks. Two patient populations were evaluated in this study: the Evaluable patient population had at least 10 percent of the cells in their primary tumor sample test positive for the AR and had at least one follow up tumor assessment, while the Intent-To-Treat population (ITT) received at least one dose of enzalutamide and their breast cancer had any amount of AR immunohistochemistry staining present. 75 patients met the criteria for the Evaluable population and a total of 118 patients were comprised of in the ITT population. There was no limit to the number of preceding treatments received.
- In the 75 Evaluable patients, CBR16 was achieved in 35% (95% CI: 24-46) counting six CR/PR (8%). Clinical benefit rate at ≥ 24 weeks (CBR24) was achieved in 29% (95% CI: 20-41). The median progression-free survival (PFS) was 14.7 weeks (95% CI: 8.1-19.3).
- In the ITT population, CBR16 was achieved in 25% (95% CI: 17-33) counting seven CR/PR (6%). CBR24 was achieved in 20% (95% CI: 14-29). Median PFS was 12.6 weeks (95% CI: 8.1-15.7).
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States.
At the end of Thursday’s trade, Shares of UBS Group AG (NYSE:UBS), lost -0.36% to $21.95.
UBS Global Asset Management Trust Company (UBS), a leading investment administration firm and a member of the UBS Global Asset Administration division of UBS Group AG, and Morningstar, Inc. (MORN), a leading provider of independent investment research, recently declared that UBS is launching a series of target-date collective investment trust funds (CITs) that seek to track the performance of the Morningstar® Lifetime Allocation Indexes. UBS anticipates to launch the CITs, which are for use exclusively by qualified retirement plans, in July. Morningstar Associates, LLC, a registered investment advisor and part of the Morningstar Investment Administration group, will serve as a nondiscretionary subadvisor with respect to the CITs. Morningstar, Inc. is the index provider.
“UBS Global Asset Management has been managing passive portfolios for more than 30 years,” said Blake Moore, Head of Americas for UBS Global Asset Administration. “Our practiced index investment professionals around the globe manage passive portfolios across asset classes counting equities, fixed income and commodities. We are happy to work with Morningstar to bring these CIT funds to defined contribution plans.”
UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide. The companys Wealth Administration division provides financial services to wealthy private clients.
Finally, Lululemon Athletica Inc. (NASDAQ:LULU), ended its last trade with 0.13% gain, and close at $61.35.
lululemon athletica, declared that the Company will be presenting at the William Blair 35th Annual Growth Stock Conference held at the Four Seasons Hotel in Chicago, Illinois on Thursday, June 11, 2015 at 9:20 am Central Daylight Time. Stuart Haselden, Chief Financial Officer will host the presentation.
lululemon athletica inc., together with its auxiliaries, designs, manufactures, and distributes athletic apparel and accessories for women, men, and female youth. It operates through two segments, Corporate-Owned Stores and Direct To Consumer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
